XYZ Venture Capital

Excited for this first set of milestones for Dust: some customers that trust and use Dust quite a bit, a first revenue milestone since starting commercialisation last fall, and the renewed trust of our investors to accelerate. Stanislas Polu and I started Dust because we’re convinced about the possibility to rethink the software layer for teams. Not by “adding AI” as an ancillary extension of existing software silos, but rather by “vectorising” more of a company’s state and operational constraints, and preparing for better, richer human/machine interfaces that leverage that vectorised layer to help “get the work done” while people focus on what they’re most uniquely qualified to do. Let people keep their workflows and software preferences, but drop the data trenches that hinder performance, collaboration and accountability. Thanks to the entire Dust team, our investors Konstantine Buhler Ross Fubini Diede van Lamoen Reshma Sohoni Carlos Eduardo Espinal MBE Philipp Moehring Andreas Klinger Pietro Bezza Sitar Teli and our extended investor family! And most importantly, thanks to our early customers and inexhaustible sources of feedback and inspiration Alan Qonto Pennylane PayFit France Payflip Photoroom Watershed Kyriba ReD Associates and many many more. It’s very early days. For more flexible machine, for this technology in particular, for Dust. Fun times, onwards! I’m enthusiastic about the short-term improvements to Dust that some users are testing and the many more to come. https://lnkd.in/eRFEXVgZ

Announcing Apex’s $95M Series B. This funding amplifies Apex, allowing us to build productized satellite buses at an industry-leading scale — empowering customers to get to space faster and more often. With this vote of confidence from investors and customers, we look forward to growing our team like never before. The round was led by XYZ Venture Capital and co-led by CRV with participation from Upfront Ventures, 8VC, Toyota Ventures, Point72 Ventures, Mirae Asset Capital, Andreessen Horowitz, Shield Capital, J2 Ventures, Ravelin, GSBackers, and more. This combination of investors brings together the best financiers from around the world, bridging the best of defense-tech, growth capital, industry experts, and more. The world is in a Space Race, and America and our allies must stay in the lead. Commercial companies are falling behind and our warfighters don't have the capabilities they need. Apex pushes humanity to greatness: providing satellite platforms that let us dominate.   Ready for the first day of the rest of your life? Join us at Apex: https://lnkd.in/gnNiUwEP

I’m excited to announce that Auxilius has raised an additional $10M, led by SignalFire, and with participation from XYZ, Renegade Partners, and CP Overture. This milestone follows an incredible 2023, with 800% revenue growth and expanded partnerships with over 50 leading biopharma companies. Of course, we would not be where we are without such an incredible team (now over 30 “Auxen” strong), or without the partnership of our earliest customers. But the biggest reason we’ve been able to establish the Auxilius platform as an essential part of the biopharma tech stack so quickly is because we are solving a real and massive problem. The Life Sciences industry continues to manage $250B in clinical R&D spend manually, in excel. We think there is a better way. The additional capital will solidify our position as a leader in Clinical Trial Financial Management (CTFM), and empower us to expand our platform to support customers more broadly in all stages of the drug development lifecycle. Getting a drug to market is extremely difficult. We believe that finance and accounting leaders should be equipped to play a role in mitigating both operational complexity and cost. If you’re as passionate about this topic as we are (or stuck in excel), we’d love to hear from you. Together, we can remove financial complexity and risk from clinical R&D to help get more life-changing drugs to market cost effectively. For more details on our journey and future plans, read our blog post (https://lnkd.in/e84jSaax), and check out this morning’s coverage from Ngai Yeung at Endpoints News

People always say they're honored and humbled about being on the Midas List. You can see that mom keeps me focused on the humble part. Midas here: https://lnkd.in/gj6xVpgm Mom and I below ....

Today we're taking the powerful data tools we've built for technical practitioners, and opening them up to everyone! We're releasing end-to-end no-code workflows with: ∑ 𝐒𝐩𝐫𝐞𝐚𝐝𝐬𝐡𝐞𝐞𝐭-𝐬𝐭𝐲𝐥𝐞 𝐜𝐚𝐥𝐜𝐮𝐥𝐚𝐭𝐢𝐨𝐧𝐬 🧮 𝐃𝐚𝐭𝐚 𝐛𝐫𝐨𝐰𝐬𝐢𝐧𝐠 🔏𝐔𝐩𝐝𝐚𝐭𝐞𝐝 𝐠𝐨𝐯𝐞𝐫𝐧𝐚𝐧𝐜𝐞 𝐟𝐞𝐚𝐭𝐮𝐫𝐞𝐬 🔮𝐀𝐈 𝐬𝐩𝐞𝐞𝐝 𝐚𝐧𝐝 𝐚𝐜𝐜𝐮𝐫𝐚𝐜𝐲 𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭𝐬 These new workflows live right alongside our existing SQL, Python, and AI tools, so everyone— regardless of technical experience— can come together in Hex to ask and answer questions with data. Watch the launch video below, and check out the blog in the comments for all the details! https://lnkd.in/gdpHuAYb

📚 New White Paper Alert: Unveiling the Hidden Crisis of Underdiagnosed #Infertility in the U.S.! Did you know that 19% of married, reproductive aged women in the U.S. experience infertility?  Shockingly, 84% of women with infertility either never receive a diagnosis or receive it too late—some waiting up to 11 years and seeing up to 5 different physicians for the answers they need to start their families. In our first white paper, we explore the causes of this epidemic and how clinical decision support software (#CDSS) can help providers like #OBGYNs, PCPs, and APPs close the gap to reproductive endocrinologists. With the LEVY Fertility Code, the first CDSS for endocrine and fertility disorders, more than 65 conditions related to infertility can be diagnosed within weeks. Key #findings from our research: 🩺 Enhanced OB-GYN Support: A staggering 97% of OB-GYNs in the U.S. want to use clinical decision support software like the “LEVY Fertility Code” to improve their ability to diagnose infertility disorders. 💪 Empowered Women: An impressive 96% of women received a previously unknown diagnosis related to their fertility when applying LEVY Health’s clinical decision support, empowering both patients and providers with vital recommendations for (their) family planning. 💰 Cost and Time Savings: By significantly reducing the time to diagnosis for over 65 conditions, our software saves patients, providers, and payors both money and time, while most importantly improving patient outcomes. ⚕️Optimized Care Coordination: LEVY Health ensures that women referred to fertility clinics are suitable candidates for #IVF, that they are well-informed about the process, and that they are fully prepared for their initial doctor's appointment to plan and begin treatment. Download our white paper to learn more about the causes of underdiagnosis and discover potential solutions to an industry problem. https://lnkd.in/eWMrYViX ⬇️ Link in comments ⬇️ #ReproductiveCare #IVF #Whitepaper #Research #FertilityInsights